Contemporary management of localized resectable pancreatic cancer

Anuhya Kommalapati, Sri Harsha Tella, Gaurav Goyal, Wen Wee Ma, Amit Mahipal

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Pancreatic cancer is the thirdmost common cause of cancer deaths in the United States. Surgical resection with negative margins still constitutes the cornerstone of potentially curative therapy, but is possible only in 15-20% of patients at the time of initial diagnosis. Accumulating evidence suggests that the neoadjuvant approach may improve R0 resection rate in localized resectable and borderline resectable diseases, and potentially downstage locally advanced disease to achieve surgical resection, though the impact on survival is to be determined. Despite advancements in the last decade in developing effective combinational chemo-radio therapeutic options, preoperative treatment strategies, and better peri-operative care, pancreatic cancer continues to carry a dismal prognosis in the majority. Prodigious efforts are currently being made in optimizing the neoadjuvant therapy with a better toxicity profile, developing novel agents, imaging techniques, and identification of biomarkers for the disease. Advancement in our understanding of the tumor microenvironment and molecular pathology is urgently needed to facilitate the development of novel targeted and immunotherapies for this setting. In this review, we detail the current literature on contemporary management of resectable, borderline resectable and locally advanced pancreatic cancer with a focus on future directions in the field.

Original languageEnglish (US)
Article number24
JournalCancers
Volume10
Issue number1
DOIs
StatePublished - Jan 20 2018

Fingerprint

Pancreatic Neoplasms
Neoadjuvant Therapy
Tumor Microenvironment
Molecular Pathology
Radio
Immunotherapy
Cause of Death
Therapeutics
Biomarkers
Survival
Neoplasms

Keywords

  • 5-fluorouracil
  • FOLFIRNOX
  • Gemcitabine
  • Neoadjuvant therapy
  • Pancreatic cancer
  • R0 resection

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Contemporary management of localized resectable pancreatic cancer. / Kommalapati, Anuhya; Tella, Sri Harsha; Goyal, Gaurav; Ma, Wen Wee; Mahipal, Amit.

In: Cancers, Vol. 10, No. 1, 24, 20.01.2018.

Research output: Contribution to journalReview article

Kommalapati, Anuhya ; Tella, Sri Harsha ; Goyal, Gaurav ; Ma, Wen Wee ; Mahipal, Amit. / Contemporary management of localized resectable pancreatic cancer. In: Cancers. 2018 ; Vol. 10, No. 1.
@article{bc933ad92ab64688b7fab6018c96e070,
title = "Contemporary management of localized resectable pancreatic cancer",
abstract = "Pancreatic cancer is the thirdmost common cause of cancer deaths in the United States. Surgical resection with negative margins still constitutes the cornerstone of potentially curative therapy, but is possible only in 15-20{\%} of patients at the time of initial diagnosis. Accumulating evidence suggests that the neoadjuvant approach may improve R0 resection rate in localized resectable and borderline resectable diseases, and potentially downstage locally advanced disease to achieve surgical resection, though the impact on survival is to be determined. Despite advancements in the last decade in developing effective combinational chemo-radio therapeutic options, preoperative treatment strategies, and better peri-operative care, pancreatic cancer continues to carry a dismal prognosis in the majority. Prodigious efforts are currently being made in optimizing the neoadjuvant therapy with a better toxicity profile, developing novel agents, imaging techniques, and identification of biomarkers for the disease. Advancement in our understanding of the tumor microenvironment and molecular pathology is urgently needed to facilitate the development of novel targeted and immunotherapies for this setting. In this review, we detail the current literature on contemporary management of resectable, borderline resectable and locally advanced pancreatic cancer with a focus on future directions in the field.",
keywords = "5-fluorouracil, FOLFIRNOX, Gemcitabine, Neoadjuvant therapy, Pancreatic cancer, R0 resection",
author = "Anuhya Kommalapati and Tella, {Sri Harsha} and Gaurav Goyal and Ma, {Wen Wee} and Amit Mahipal",
year = "2018",
month = "1",
day = "20",
doi = "10.3390/cancers10010024",
language = "English (US)",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - Contemporary management of localized resectable pancreatic cancer

AU - Kommalapati, Anuhya

AU - Tella, Sri Harsha

AU - Goyal, Gaurav

AU - Ma, Wen Wee

AU - Mahipal, Amit

PY - 2018/1/20

Y1 - 2018/1/20

N2 - Pancreatic cancer is the thirdmost common cause of cancer deaths in the United States. Surgical resection with negative margins still constitutes the cornerstone of potentially curative therapy, but is possible only in 15-20% of patients at the time of initial diagnosis. Accumulating evidence suggests that the neoadjuvant approach may improve R0 resection rate in localized resectable and borderline resectable diseases, and potentially downstage locally advanced disease to achieve surgical resection, though the impact on survival is to be determined. Despite advancements in the last decade in developing effective combinational chemo-radio therapeutic options, preoperative treatment strategies, and better peri-operative care, pancreatic cancer continues to carry a dismal prognosis in the majority. Prodigious efforts are currently being made in optimizing the neoadjuvant therapy with a better toxicity profile, developing novel agents, imaging techniques, and identification of biomarkers for the disease. Advancement in our understanding of the tumor microenvironment and molecular pathology is urgently needed to facilitate the development of novel targeted and immunotherapies for this setting. In this review, we detail the current literature on contemporary management of resectable, borderline resectable and locally advanced pancreatic cancer with a focus on future directions in the field.

AB - Pancreatic cancer is the thirdmost common cause of cancer deaths in the United States. Surgical resection with negative margins still constitutes the cornerstone of potentially curative therapy, but is possible only in 15-20% of patients at the time of initial diagnosis. Accumulating evidence suggests that the neoadjuvant approach may improve R0 resection rate in localized resectable and borderline resectable diseases, and potentially downstage locally advanced disease to achieve surgical resection, though the impact on survival is to be determined. Despite advancements in the last decade in developing effective combinational chemo-radio therapeutic options, preoperative treatment strategies, and better peri-operative care, pancreatic cancer continues to carry a dismal prognosis in the majority. Prodigious efforts are currently being made in optimizing the neoadjuvant therapy with a better toxicity profile, developing novel agents, imaging techniques, and identification of biomarkers for the disease. Advancement in our understanding of the tumor microenvironment and molecular pathology is urgently needed to facilitate the development of novel targeted and immunotherapies for this setting. In this review, we detail the current literature on contemporary management of resectable, borderline resectable and locally advanced pancreatic cancer with a focus on future directions in the field.

KW - 5-fluorouracil

KW - FOLFIRNOX

KW - Gemcitabine

KW - Neoadjuvant therapy

KW - Pancreatic cancer

KW - R0 resection

UR - http://www.scopus.com/inward/record.url?scp=85041364904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041364904&partnerID=8YFLogxK

U2 - 10.3390/cancers10010024

DO - 10.3390/cancers10010024

M3 - Review article

AN - SCOPUS:85041364904

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

M1 - 24

ER -